Overview
Fourth branchial cleft anomaly (also known as fourth branchial pouch anomaly, fourth pharyngeal arch anomaly, or fourth branchial cleft cyst/sinus/fistula) is a rare congenital malformation arising from incomplete obliteration of the fourth branchial apparatus during embryonic development. These anomalies are among the rarest of all branchial cleft defects, accounting for a very small proportion of branchial anomalies. The condition primarily affects the neck and may involve the thyroid gland, pyriform sinus (a recess in the throat), and surrounding structures of the lower neck. Clinically, fourth branchial cleft anomalies most commonly present as recurrent neck abscesses, acute suppurative thyroiditis (infected and inflamed thyroid gland), or a sinus tract that typically courses from the pyriform sinus apex downward through the neck, often on the left side. Patients may experience recurrent episodes of neck swelling, pain, fever, and difficulty swallowing. In neonates and infants, the anomaly may present as respiratory distress or a neck mass. The condition can be misdiagnosed as a thyroid abscess or other neck pathology, leading to delayed diagnosis. Diagnosis is established through imaging studies such as CT scan, MRI, or barium swallow demonstrating a tract originating from the pyriform sinus. Direct laryngoscopy may also reveal the internal opening. Treatment is primarily surgical, involving complete excision of the sinus tract or fistula to prevent recurrence. In some cases, endoscopic cauterization or chemocauterization of the internal opening in the pyriform sinus has been used as a less invasive alternative. Acute infections are managed with antibiotics and drainage prior to definitive surgical repair. Recurrence is possible if the tract is not completely removed.
Sporadic
Usually appears on its own, not inherited from a parent
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventMYCAPSSA (formerly Octreolin): FDA approved
Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableMYCAPSSA (formerly Octreolin)
Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Clinical Trials
View all trials with filters →No actively recruiting trials found for Fourth branchial cleft anomaly at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Fourth branchial cleft anomaly.
Community
No community posts yet. Be the first to share your experience with Fourth branchial cleft anomaly.
Start the conversation →Latest news about Fourth branchial cleft anomaly
No recent news articles for Fourth branchial cleft anomaly.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Fourth branchial cleft anomaly
What is Fourth branchial cleft anomaly?
Fourth branchial cleft anomaly (also known as fourth branchial pouch anomaly, fourth pharyngeal arch anomaly, or fourth branchial cleft cyst/sinus/fistula) is a rare congenital malformation arising from incomplete obliteration of the fourth branchial apparatus during embryonic development. These anomalies are among the rarest of all branchial cleft defects, accounting for a very small proportion of branchial anomalies. The condition primarily affects the neck and may involve the thyroid gland, pyriform sinus (a recess in the throat), and surrounding structures of the lower neck. Clinically, f
How is Fourth branchial cleft anomaly inherited?
Fourth branchial cleft anomaly follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat Fourth branchial cleft anomaly?
9 specialists and care centers treating Fourth branchial cleft anomaly are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Fourth branchial cleft anomaly?
1 patient support program are currently tracked on UniteRare for Fourth branchial cleft anomaly. See the treatments and support programs sections for copay assistance, eligibility, and contact details.